ponezumab (PF-04360365) / Pfizer - LARVOL DELTA

Intellect Neurosciences announces new findings supporting its patented ANTISENILIN platform technology for the treatment of Alzheimer's disease (Intellect) - Intellect announced new findings on ponezumab (PF-04360365); According to new data drug exposure and plasma amyloid beta levels increased with increasing dose; After 26 weeks, 100mg/kg group had greater plasma levels of A1-x and Ax-40 in comparison to vehicle group (p<0.001); This idea is consistent with results from solanezumab P3 clinical trials, which has shown modest but consistent clinical benefit from reducing A beta monomers in brain.

Preclinical • Alzheimer's Disease

Multiple intravenous dose study of PF-04360365 in Japanese patients with mild to moderate Alzheimer's disease (clinicaltrials.gov) - P1, N=8; Active, not recruiting → Completed

Trial completion • Alzheimer's Disease

Intellect Neurosciences receives notice of allowance from United States Patent and Trademark Office for its Antisenilin Alzheimer's disease immunotherapy technology platform (PRNewswire) - A P1 study to determine effect of PF-04360365 on clearance of β amyloid from cerebrospinal fluid in patients with Alzheimer's disease & healthy volunteers is currently recruiting pts; This trial, which is scheduled to complete in Aug 2012, follows other completed P1 and P2 trials

Anticipated P1 trial completion • Ongoing enrollment • Alzheimer's Disease

Pfizer pipeline (Pfizer) - Ponezumab (PF-04360365) was discontinued from development since May 12 '11

Drug discontinuation • Alzheimer's Disease

Chronic administration of an aglycosylated murine antibody of ponezumab does not worsen microhemorrhages in aged Tg2576 mice (Curr Alzheimer Res) - Intraperitoneal administration of a murine surrogate of ponezumab to aged Tg2576 mice for up to 6 mos did not produce any compound-related brain microhemorrhage or other pathologies

Preclinical-animal • Alzheimer's Disease